Tackling resistant infections with virulence inhibition.


Increase in resistant infections

Bacteria that cause disease are becoming more resistant to  standard antibiotics. Expanding the toolkit available to include new types of treatments can guardrail our societies to the increasing burden of resistant infections.

Learn More

Dual-acting first-in-class virulence inhibitors

Using novel chemistry to disarm bacteria of their weapons  and strip them from their armour, the Arivin's leads dual mechanism of action targets  bacterial infections without killing the bacteria or stopping its growth.

Due to reduced selection pressure, the non-bactericidal virulence inhibition is less prone to confer resistance. The compounds increase the potency of traditional antibiotics and reduce target bacteria's resistance.  Importantly, the mechanism reduces expression of toxins which reduces inflammation and tissue damage at the site of infection.

Learn More


Scientists invent. Entrepreneurs execute.
Investors invest.
We are raising a seed round to take a  virulence inhibitor to clinical trials.
Request a non-confidential pitch Deck